secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viridian Therapeutics, Inc.\DE (VRDN)
CIK:        0001590750
Form:       8-K
Filed at:   2025-07-30T23:59:59+00:00
Accession:  0001193125-25-168614
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viridian Therapeutics licenses veligrotug, VRDN-003 to Kissei for Japan; $70M upfront, up to $315M milestones
--------------------------------------------------------------------------------

- Upfront payment of $70M; up to $315M in development, regulatory, and commercial milestones.
- Tiered royalties on Japan net sales in the 20s to mid-30s percent range.
- Kissei gets exclusive Japan rights; Viridian retains manufacturing/supply responsibilities except limited cases.
- Veligrotug (VRDN-001) and VRDN-003 are anti-IGF-1R antibodies targeting thyroid eye disease.
- THRIVE and THRIVE-2 phase 3 trials for veligrotug met all primary and secondary endpoints.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590750/000119312525168614/0001193125-25-168614-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590750/000119312525168614/d24708d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-168614

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer